PDS Biotechnology (NASDAQ:PDSB) Stock Rating Upgraded by StockNews.com

PDS Biotechnology (NASDAQ:PDSB) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Friday.

A number of other brokerages have also recently issued reports on PDSB. HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of PDS Biotechnology in a report on Thursday, October 24th. Alliance Global Partners upgraded shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, PDS Biotechnology has an average rating of “Buy” and an average target price of $14.25.

PDS Biotechnology Trading Up 0.3 %

Shares of PDSB stock traded up $0.01 on Friday, reaching $3.20. 250,080 shares of the stock were exchanged, compared to its average volume of 610,675. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.84 and a quick ratio of 3.84. PDS Biotechnology has a one year low of $2.53 and a one year high of $6.85. The stock has a market cap of $117.82 million, a PE ratio of -2.62 and a beta of 1.90. The stock has a 50 day moving average price of $3.24 and a 200 day moving average price of $3.27.

PDS Biotechnology (NASDAQ:PDSB) last issued its earnings results on Tuesday, August 13th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same quarter in the prior year, the firm posted ($0.37) EPS. Equities research analysts forecast that PDS Biotechnology will post -1.24 EPS for the current fiscal year.

Hedge Funds Weigh In On PDS Biotechnology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in shares of PDS Biotechnology by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock valued at $6,288,000 after purchasing an additional 82,135 shares in the last quarter. Blair William & Co. IL boosted its position in PDS Biotechnology by 204.4% during the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after acquiring an additional 81,743 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in PDS Biotechnology during the 2nd quarter worth approximately $146,000. Squarepoint Ops LLC bought a new position in shares of PDS Biotechnology during the 2nd quarter worth approximately $120,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of PDS Biotechnology in the second quarter valued at approximately $115,000. 26.84% of the stock is owned by institutional investors and hedge funds.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.